Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities

Nat Immunol. 2023 Jun;24(6):966-978. doi: 10.1038/s41590-023-01508-y. Epub 2023 May 29.

Abstract

High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specific B cells, and CD4+ and CD8+ T cells. In First Nations participants, RBD IgG antibody titers were correlated with body mass index and negatively correlated with age. Reduced RBD antibodies, spike-specific B cells and follicular helper T cells were found in vaccinated participants with chronic conditions (diabetes, renal disease) and were strongly associated with altered glycosylation of IgG and increased interleukin-18 levels in the plasma. These immune perturbations were also found in non-Indigenous people with comorbidities, indicating that they were related to comorbidities rather than ethnicity. However, our study is of a great importance to First Nations peoples who have disproportionate rates of chronic comorbidities and provides evidence of robust immune responses after COVID-19 vaccination in Indigenous people.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Australia / epidemiology
  • BNT162 Vaccine
  • CD8-Positive T-Lymphocytes
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Immunity
  • Immunoglobulin G
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine
  • Immunoglobulin G
  • Antibodies, Neutralizing
  • Antibodies, Viral